{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:40:26Z","timestamp":1793324426566,"version":"4.5.0"},"reference-count":430,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.<\/jats:p>","DOI":"10.1093\/neuonc\/noae082","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T08:56:24Z","timestamp":1714640184000},"page":"1742-1780","source":"Crossref","is-referenced-by-count":164,"title":["Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients"],"prefix":"10.1093","volume":"26","author":[{"given":"Justin Z","family":"Wang","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P","family":"Landry","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Neurological Surgery, and Pathology, University of California San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital Heidelberg and German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-9981","authenticated-orcid":false,"given":"Kyle M","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Goldbrunner","sequence":"additional","affiliation":[{"name":"Center of Neurosurgery, Department of General Neurosurgery, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeor S","family":"Yefet","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg C","family":"Tonn","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Munich LMU , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Gui","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn T","family":"Ostrom","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Central Brain Tumor Registry of the United States , Hinsdale , Illinois ,","place":["USA"]},{"name":"Department of Neurosurgery, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Barnholtz-Sloan","sequence":"additional","affiliation":[{"name":"Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute , Bethesda, Maryland ,","place":["USA"]},{"name":"Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute , Bethesda, Maryland ,","place":["USA"]},{"name":"Central Brain Tumor Registry of the United States , Hinsdale , Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Perry","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Ellenbogen","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Oliver","family":"Hanemann","sequence":"additional","affiliation":[{"name":"Peninsula Schools of Medicine, University of Plymouth University , Plymouth ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Jungwirth","sequence":"additional","affiliation":[{"name":"Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Jenkinson","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool ,","place":["UK"]},{"name":"Institute of Translational Medicine, University of Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital T\u00fcbingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]},{"name":"Cluster of Excellence (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiit I","family":"Mathiesen","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institute, Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"McDermott","sequence":"additional","affiliation":[{"name":"Division of Neuroscience, Herbert Wertheim College of Medicine, Florida International University , Miami, Florida ,","place":["USA"]},{"name":"Miami Neuroscience Institute, Baptist Health of South Florida , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Clinical Molecular Imaging, University Hospital T\u00fcbingen ,","place":["Germany"]},{"name":"Cluster of Excellence (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies,\u201d Eberhard Karls University T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybren L N","family":"Maas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Pathology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-1796","authenticated-orcid":false,"given":"Norbert","family":"Galldiks","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne ,","place":["Germany"]},{"name":"Institute of Neuroscience and Medicine (IMN-3), Research Center Juelich , Juelich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie L","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ludwig Maximilians-University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ehret","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]},{"name":"Berlin Institute of Health, Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Lamszus","sequence":"additional","affiliation":[{"name":"Laboratory for Brain Tumor Biology, University Hospital Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz L","family":"Ricklefs","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6209","authenticated-orcid":false,"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital T\u00fcbingen, Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine J","family":"Drummond","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Royal Melbourne Hospital , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar N","family":"Pathmanaban","sequence":"additional","affiliation":[{"name":"Division of Neuroscience and Experimental Psychology, Manchester Centre for Clinical Neurosciences, Geoffrey Jefferson Brain Research Centre, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron A","family":"Cohen-Gadol","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Indiana University , Indianapolis, Indiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P","family":"Sulman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, NYU Grossman School of Medicine , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Tabouret","sequence":"additional","affiliation":[{"name":"CNRS, INP, Inst Neurophysiopathol, Aix-Marseille University , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital Magdeburg , Magdeburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moliterno","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale School of Medicine , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya (Linda)","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Department of Radiation Oncology, University Hospital , Munich ,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK) , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[{"name":"Bavarian Cancer Research Center (BZKF) , Munich ,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen , T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The International Consortium on Meningiomas (ICOM)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-7550","authenticated-orcid":false,"given":"Kenneth","family":"Aldape","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Short","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research, St James\u2019s University Hospital , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Nassiri","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6637-4502","authenticated-orcid":false,"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2024100317500718400_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20142020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro-Oncology."},{"key":"2024100317500718400_CIT0002","first-page":"i5","article-title":"The joint impacts of sex and race\/ethnicity on incidence of grade 1 versus grades 2-3 meningioma across the lifespan","volume":"5","author":"Walsh","year":"2023","journal-title":"Neurooncol. Adv."},{"issue":"8","key":"2024100317500718400_CIT0003","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024100317500718400_CIT0004","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3171\/2022.1.JNS212723","article-title":"Granular clinical history and outcome in 51 patients with primary and secondary malignant meningioma","volume":"137","author":"Maier","year":"2022","journal-title":"J Neurosurg."},{"issue":"2","key":"2024100317500718400_CIT0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3171\/2023.6.JNS23465","article-title":"Grade 3 meningioma survival and recurrence outcomes in an international multicenter cohort","volume":"140","author":"Tosefsky","year":"2023","journal-title":"J Neurosurg."},{"issue":"15","key":"2024100317500718400_CIT0006","doi-asserted-by":"crossref","first-page":"E886","DOI":"10.1097\/BRS.0000000000000974","article-title":"Descriptive epidemiology of spinal meningiomas in the United States","volume":"40","author":"Kshettry","year":"2015","journal-title":"Spine (Phila Pa 1976)"},{"issue":"11","key":"2024100317500718400_CIT0007","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/neuonc\/noy077","article-title":"Genome-wide association analysis identifies a meningioma risk locus at 11p15.5","volume":"20","author":"Claus","year":"2018","journal-title":"Neuro Oncol"},{"issue":"9","key":"2024100317500718400_CIT0008","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/ng.879","article-title":"Common variation at 10p12.31 near MLLT10 influences meningioma risk","volume":"43","author":"Dobbins","year":"2011","journal-title":"Nat Genet."},{"issue":"1","key":"2024100317500718400_CIT0009","first-page":"vdac044","article-title":"Pleiotropic MLLT10 variation confers risk of meningioma and estrogen-mediated cancers","volume":"4","author":"Walsh","year":"2022","journal-title":"Neurooncol. Adv."},{"issue":"1","key":"2024100317500718400_CIT0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41467-017-00174-7","article-title":"Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas","volume":"8","author":"Agnihotri","year":"2017","journal-title":"Nat Commun."},{"issue":"6","key":"2024100317500718400_CIT0011","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3171\/jns.2004.100.6.1002","article-title":"Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic characteristics","volume":"100","author":"Al-Mefty","year":"2004","journal-title":"J Neurosurg."},{"key":"2024100317500718400_CIT0012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.wneu.2016.09.094","article-title":"Radiation-induced meningiomas: An exhaustive review of the literature","volume":"97","author":"Yamanaka","year":"2017","journal-title":"World Neurosurg"},{"key":"2024100317500718400_CIT0013","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-031-29750-2_12","article-title":"Radiation-induced meningiomas","volume":"1416","author":"Wang","year":"2023","journal-title":"Adv Exp Med Biol."},{"issue":"7","key":"2024100317500718400_CIT0014","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jnen\/59.7.614","article-title":"Radiation-induced meningioma: A distinct molecular genetic pattern","volume":"59","author":"Shoshan","year":"2000","journal-title":"J Neuropathol Exp Neurol."},{"issue":"5","key":"2024100317500718400_CIT0015","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/FOC\/2008\/24\/5\/E7","article-title":"Radiation-induced meningioma","volume":"24","author":"Umansky","year":"2008","journal-title":"Neurosurg Focus."},{"issue":"4","key":"2024100317500718400_CIT0016","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3171\/2013.12.JNS131170","article-title":"Endogenous and exogenous hormone exposure and the risk of meningioma in men","volume":"120","author":"Schildkraut","year":"2014","journal-title":"J Neurosurg."},{"issue":"3","key":"2024100317500718400_CIT0017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3171\/2012.9.JNS12811","article-title":"Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females","volume":"118","author":"Claus","year":"2013","journal-title":"J Neurosurg."},{"issue":"6","key":"2024100317500718400_CIT0018","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/1055-9965.EPI-11-1059","article-title":"Cigarette smoking and risk of meningioma: The effect of gender","volume":"21","author":"Claus","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"36","key":"2024100317500718400_CIT0019","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.27.0090","article-title":"Population-based risks of CNS tumors in survivors of childhood cancer: The British Childhood Cancer Survivor Study","volume":"28","author":"Taylor","year":"2010","journal-title":"J Clin Oncol."},{"issue":"12","key":"2024100317500718400_CIT0020","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/jamaoncol.2022.4425","article-title":"Pooled analysis of meningioma risk following treatment for childhood cancer","volume":"8","author":"Withrow","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"2024100317500718400_CIT0021","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2007.14.2133","article-title":"Is there an association between meningioma and hormone replacement therapy","volume":"26","author":"Blitshteyn","year":"2008","journal-title":"J Clin Oncol."},{"issue":"17","key":"2024100317500718400_CIT0022","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jnci\/84.17.1346","article-title":"Association between brain tumors and menopausal status","volume":"84","author":"Schlehofer","year":"1992","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"2024100317500718400_CIT0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ijc.2910510105","article-title":"Risk factors for tumors of the brain and meninges: Results from the Adelaide Adult Brain Tumor Study","volume":"51","author":"Ryan","year":"1992","journal-title":"Int J Cancer."},{"issue":"5","key":"2024100317500718400_CIT0024","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3171\/jns.2003.99.5.0848","article-title":"Sex steroid hormone exposures and risk for meningioma","volume":"99","author":"Jhawar","year":"2003","journal-title":"J Neurosurg."},{"issue":"7","key":"2024100317500718400_CIT0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/aje\/kwj254","article-title":"Risk of brain tumors associated with exposure to exogenous female sex hormones","volume":"164","author":"Wigertz","year":"2006","journal-title":"Am J Epidemiol."},{"issue":"5","key":"2024100317500718400_CIT0026","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ijc.20776","article-title":"Reproductive and hormonal factors and risk of brain tumors in adult females","volume":"114","author":"Hatch","year":"2005","journal-title":"Int J Cancer."},{"issue":"1","key":"2024100317500718400_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-6-152","article-title":"Hormonal exposures and the risk of intracranial meningioma in women: A population-based case-control study","volume":"6","author":"Custer","year":"2006","journal-title":"BMC Cancer"},{"issue":"5","key":"2024100317500718400_CIT0028","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/ijc.21950","article-title":"Association of meningioma with reproductive factors","volume":"119","author":"Lee","year":"2006","journal-title":"Int J Cancer."},{"key":"2024100317500718400_CIT0029","doi-asserted-by":"crossref","first-page":"n37","DOI":"10.1136\/bmj.n37","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2024100317500718400_CIT0030","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1038\/s41598-021-88742-2","article-title":"The risk of developing a meningioma during and after pregnancy","volume":"11","author":"Pettersson-Segerlind","year":"2021","journal-title":"Sci Rep."},{"issue":"1","key":"2024100317500718400_CIT0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10143-016-0762-3","article-title":"Unique features of pregnancy-related meningiomas: Lessons learned from 148 reported cases and theoretical implications of a prolactin modulated pathogenesis","volume":"41","author":"Laviv","year":"2018","journal-title":"Neurosurg Rev."},{"issue":"5","key":"2024100317500718400_CIT0032","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1227\/NEU.0b013e31826adf65","article-title":"Meningiomas in pregnancy: A clinicopathologic study of 17 cases","volume":"71","author":"Lusis","year":"2012","journal-title":"Neurosurgery."},{"issue":"4","key":"2024100317500718400_CIT0033","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell."},{"issue":"4","key":"2024100317500718400_CIT0034","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/gcc.10282","article-title":"NF2: The wizardry of merlin","volume":"38","author":"Xiao","year":"2003","journal-title":"Genes Chromosomes Cancer."},{"issue":"2","key":"2024100317500718400_CIT0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/ijms22020690","article-title":"Neurofibromatosis Type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis","volume":"22","author":"Bachir","year":"2021","journal-title":"Int J Mol Sci ."},{"issue":"7","key":"2024100317500718400_CIT0036","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1541-7786.MCR-12-0116","article-title":"Yes-associated protein 1 is activated and functions as an oncogene in meningiomas","volume":"10","author":"Baia","year":"2012","journal-title":"Mol Cancer Res."},{"issue":"5","key":"2024100317500718400_CIT0037","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet."},{"issue":"1","key":"2024100317500718400_CIT0038","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","article-title":"Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic","volume":"8","author":"Williams","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"6123","key":"2024100317500718400_CIT0039","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science."},{"issue":"10","key":"2024100317500718400_CIT0040","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ng.3651","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark","year":"2016","journal-title":"Nat Genet."},{"issue":"3","key":"2024100317500718400_CIT0041","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet."},{"issue":"5","key":"2024100317500718400_CIT0042","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024100317500718400_CIT0043","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3892\/ol.2014.2042","article-title":"EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas","volume":"7","author":"Bujko","year":"2014","journal-title":"Oncol Lett"},{"issue":"5","key":"2024100317500718400_CIT0044","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/neuonc\/now029","article-title":"PIK3CA mutations in meningioma","volume":"18","author":"Zadeh","year":"2016","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024100317500718400_CIT0045","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas","volume":"133","author":"Youngblood","year":"2019","journal-title":"J Neurosurg."},{"issue":"6","key":"2024100317500718400_CIT0046","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00401-023-02635-4","article-title":"Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes","volume":"146","author":"Boetto","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2024100317500718400_CIT0047","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3171\/2015.3.PEDS14417","article-title":"SMARCE1 mutations in pediatric clear cell meningioma: Case report","volume":"16","author":"Evans","year":"2015","journal-title":"J Neurosurg Pediatr"},{"issue":"2","key":"2024100317500718400_CIT0048","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10048-015-0472-y","article-title":"A heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening","volume":"17","author":"Gerkes","year":"2016","journal-title":"Neurogenetics"},{"issue":"4","key":"2024100317500718400_CIT0049","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bpa.12524","article-title":"Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: A comprehensive immunophenotypical and molecular analysis","volume":"28","author":"Tauziede-Espariat","year":"2018","journal-title":"Brain Pathol."},{"issue":"6","key":"2024100317500718400_CIT0050","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41588-022-01077-0","article-title":"SMARCE1 deficiency generates a targetable mSWI\/SNF dependency in clear cell meningioma","volume":"54","author":"St. Pierre","year":"2022","journal-title":"Nat Genet."},{"issue":"2","key":"2024100317500718400_CIT0051","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00401-020-02247-2","article-title":"Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1","volume":"141","author":"Sievers","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2024100317500718400_CIT0052","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jclinpath-2021-207952","article-title":"BAP1-deficient meningioma presenting with trabecular architecture and cytokeratin expression: A report of two cases and review of the literature","volume":"76","author":"Landry","year":"2021","journal-title":"J Clin Pathol."},{"issue":"11","key":"2024100317500718400_CIT0053","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","article-title":"BAP1 mutations in high-grade meningioma: Implications for patient care","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro-Oncology."},{"issue":"1","key":"2024100317500718400_CIT0054","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00401-020-02161-7","article-title":"Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features","volume":"140","author":"Williams","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2024100317500718400_CIT0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/jnnp-2019-322257","article-title":"Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: An individual patient data meta-analysis","volume":"91","author":"Mirian","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"2024100317500718400_CIT0056","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"6358","key":"2024100317500718400_CIT0057","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aao0535","article-title":"Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism","volume":"357","author":"Chiba","year":"2017","journal-title":"Science."},{"issue":"12","key":"2024100317500718400_CIT0058","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","article-title":"TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma","volume":"20","author":"Spiegl-Kreinecker","year":"2018","journal-title":"Neuro-Oncology."},{"issue":"6","key":"2024100317500718400_CIT0059","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cancergen.2015.03.005","article-title":"ARID1A and TERT promoter mutations in dedifferentiated meningioma","volume":"208","author":"Abedalthagafi","year":"2015","journal-title":"Cancer Gen"},{"issue":"8","key":"2024100317500718400_CIT0060","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1007\/s00432-022-04442-y","article-title":"ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas","volume":"149","author":"Chaluts","year":"2023","journal-title":"J Cancer Res Clin Oncol."},{"issue":"11","key":"2024100317500718400_CIT0061","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s00432-021-03586-7","article-title":"SWI\/SNF chromatin remodeling complex alterations in meningioma","volume":"147","author":"Gill","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"issue":"6","key":"2024100317500718400_CIT0062","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/neuros\/nyy121","article-title":"Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease","volume":"83","author":"Kerr","year":"2018","journal-title":"Neurosurgery."},{"issue":"3","key":"2024100317500718400_CIT0063","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1055\/s-0036-1584265","article-title":"Multiple meningiomas in a patient with cowden syndrome","volume":"77","author":"Pain","year":"2016","journal-title":"J Neurol Surg Rep"},{"issue":"7874","key":"2024100317500718400_CIT0064","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature."},{"key":"2024100317500718400_CIT0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): A clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J Rare Dis."},{"issue":"9","key":"2024100317500718400_CIT0066","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","article-title":"Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation","volume":"24","author":"Plotkin","year":"2022","journal-title":"Genet Med."},{"issue":"10","key":"2024100317500718400_CIT0067","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","article-title":"Clinical features of schwannomatosis: A retrospective analysis of 87 patients","volume":"17","author":"Merker","year":"2012","journal-title":"Oncologist."},{"issue":"4","key":"2024100317500718400_CIT0068","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/path.4427","article-title":"Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas","volume":"234","author":"Smith","year":"2014","journal-title":"J Pathol."},{"issue":"3","key":"2024100317500718400_CIT0069","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ng.2552","article-title":"Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas","volume":"45","author":"Smith","year":"2013","journal-title":"Nat Genet."},{"key":"2024100317500718400_CIT0070","doi-asserted-by":"crossref","first-page":"721712","DOI":"10.3389\/fonc.2021.721712","article-title":"Germline BAP1 mutation in a family with multi-generational meningioma with rhabdoid features: A case series and literature review","volume":"11","author":"Prasad","year":"2021","journal-title":"Front Oncol."},{"issue":"4","key":"2024100317500718400_CIT0071","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0072","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40478-023-01505-0","article-title":"Mutational signature of extracranial meningioma metastases and their respective primary tumors","volume":"11","author":"Biczok","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"2024100317500718400_CIT0073","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: Malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J Transl Med."},{"issue":"3","key":"2024100317500718400_CIT0074","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ajhg.2012.07.015","article-title":"Loss of SUFU function in familial multiple meningioma","volume":"91","author":"Aavikko","year":"2012","journal-title":"Am J Hum Genet."},{"issue":"9","key":"2024100317500718400_CIT0075","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaneurol.2017.1406","article-title":"Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults","volume":"74","author":"Pathmanaban","year":"2017","journal-title":"JAMA Neurol"},{"issue":"36","key":"2024100317500718400_CIT0076","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1200\/JCO.2014.58.2569","article-title":"Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol."},{"key":"2024100317500718400_CIT0077","article-title":"Werner Syndrome","volume-title":"GeneReviews(\u00ae)","author":"Oshima","year":"1993"},{"issue":"5","key":"2024100317500718400_CIT0078","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ped.12461","article-title":"Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review","volume":"56","author":"Fujii","year":"2014","journal-title":"Pediatr Int."},{"issue":"8","key":"2024100317500718400_CIT0079","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ctrv.2010.04.002","article-title":"Cowden syndrome","volume":"36","author":"Farooq","year":"2010","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"2024100317500718400_CIT0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ijc.2910560310","article-title":"Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression","volume":"56","author":"Lindblom","year":"1994","journal-title":"Int J Cancer."},{"issue":"15","key":"2024100317500718400_CIT0081","first-page":"3226","article-title":"Identification of a consistent region of allelic loss on 1p32 in meningiomas: Correlation with increased morbidity","volume":"58","author":"Sulman","year":"1998","journal-title":"Cancer Res."},{"issue":"6","key":"2024100317500718400_CIT0082","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnen\/60.6.628","article-title":"Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: Diagnostic and prognostic implications","volume":"60","author":"Cai","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3 Pt 1","key":"2024100317500718400_CIT0083","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1158\/1078-0432.CCR-05-1480","article-title":"The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse","volume":"12","author":"Espinosa","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"17","key":"2024100317500718400_CIT0084","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1200\/JCO.2003.07.156","article-title":"New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology","volume":"21","author":"Maillo","year":"2003","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024100317500718400_CIT0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1227\/01.NEU.0000311062.72626.D6","article-title":"Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas","volume":"62","author":"Ketter","year":"2008","journal-title":"Neurosurgery."},{"issue":"7","key":"2024100317500718400_CIT0086","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/ijc.22855","article-title":"Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas","volume":"121","author":"Ketter","year":"2007","journal-title":"Int J Cancer."},{"issue":"4","key":"2024100317500718400_CIT0087","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/sj.onc.1206623","article-title":"Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34","volume":"23","author":"Sulman","year":"2004","journal-title":"Oncogene."},{"issue":"5","key":"2024100317500718400_CIT0088","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2011.2.FOCUS1116","article-title":"The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments","volume":"30","author":"Choy","year":"2011","journal-title":"Neurosurg Focus."},{"issue":"1","key":"2024100317500718400_CIT0089","first-page":"1","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"npj Genomic Med."},{"issue":"4","key":"2024100317500718400_CIT0090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1750-3639.2009.00356.x","article-title":"Genomic landscape of meningiomas","volume":"20","author":"Lee","year":"2010","journal-title":"Brain Pathol"},{"issue":"3","key":"2024100317500718400_CIT0091","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3171\/2015.6.JNS15591","article-title":"Genomic landscape of intracranial meningiomas","volume":"125","author":"Bi","year":"2016","journal-title":"J Neurosurg."},{"issue":"5","key":"2024100317500718400_CIT0092","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2021","journal-title":"Neuro Oncol"},{"issue":"34","key":"2024100317500718400_CIT0093","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: A multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol."},{"issue":"6","key":"2024100317500718400_CIT0094","first-page":"1601","article-title":"Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence","volume":"39","author":"Urbschat","year":"2011","journal-title":"Int J Oncol."},{"issue":"1","key":"2024100317500718400_CIT0095","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1038\/s41467-023-41926-y","article-title":"Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas","volume":"14","author":"Youngblood","year":"2023","journal-title":"Nat Commun."},{"issue":"2","key":"2024100317500718400_CIT0096","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","article-title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas","volume":"159","author":"Bostr\u00f6m","year":"2001","journal-title":"Am J Pathol."},{"key":"2024100317500718400_CIT0097","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in Cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"2024100317500718400_CIT0098","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00401-023-02571-3","article-title":"Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas","volume":"146","author":"Wang","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2024100317500718400_CIT0099","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00401-023-02543-7","article-title":"Even heterozygous loss of CDKN2A\/B greatly accelerates recurrence in aggressive meningioma","volume":"145","author":"Khan","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2024100317500718400_CIT0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1750-3639.2002.tb00433.x","article-title":"A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas","volume":"12","author":"Perry","year":"2002","journal-title":"Brain Pathol."},{"issue":"3","key":"2024100317500718400_CIT0101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"9","key":"2024100317500718400_CIT0102","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","article-title":"The WHO 2021 Classification of Central Nervous System tumours: A practical update on what neurosurgeons need to know-a minireview","volume":"164","author":"Torp","year":"2022","journal-title":"Acta Neurochir (Wien)."},{"issue":"10","key":"2024100317500718400_CIT0103","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/neuonc\/nox071","article-title":"Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: A systematic review","volume":"19","author":"Brokinkel","year":"2017","journal-title":"Neuro Oncol"},{"issue":"9","key":"2024100317500718400_CIT0104","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/neuonc\/noac032","article-title":"The impact of brain invasion criteria on the incidence and distribution of WHO grade 1, 2, and 3 meningiomas","volume":"24","author":"Rebchuk","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"4","key":"2024100317500718400_CIT0105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3171\/2023.2.JNS222751","article-title":"Is brain invasion sufficient as a stand-alone criterion for grading atypical meningioma","volume":"139","author":"Li","year":"2023","journal-title":"J Neurosurg."},{"issue":"2","key":"2024100317500718400_CIT0106","doi-asserted-by":"crossref","first-page":"e13048","DOI":"10.1111\/bpa.13048","article-title":"Molecular neuropathology of brain-invasive meningiomas","volume":"32","author":"von Spreckelsen","year":"2022","journal-title":"Brain Pathol."},{"issue":"12","key":"2024100317500718400_CIT0107","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.3390\/cancers12123620","article-title":"CNS invasion in meningioma-how the intraoperative assessment can improve the prognostic evaluation of tumor recurrence","volume":"12","author":"Behling","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"13","key":"2024100317500718400_CIT0108","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/cancers13133259","article-title":"Brain invasion in meningioma-a prognostic potential worth exploring","volume":"13","author":"Behling","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2024100317500718400_CIT0109","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"2024100317500718400_CIT0110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","article-title":"Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma","volume":"133","author":"Olar","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2024100317500718400_CIT0111","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: Development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol."},{"issue":"13","key":"2024100317500718400_CIT0112","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1016\/j.celrep.2018.03.013","article-title":"Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation","volume":"22","author":"Vasudevan","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"2024100317500718400_CIT0113","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/nan.12571","article-title":"Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression","volume":"46","author":"Kim","year":"2020","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"43","key":"2024100317500718400_CIT0114","doi-asserted-by":"crossref","first-page":"21715","DOI":"10.1073\/pnas.1912858116","article-title":"Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors","volume":"116","author":"Patel","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2024100317500718400_CIT0115","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41598-018-19308-y","article-title":"Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression","volume":"8","author":"Parada","year":"2018","journal-title":"Sci Rep."},{"issue":"11","key":"2024100317500718400_CIT0116","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S","article-title":"Establishment of a human malignant meningioma cell line with amplified c-myc oncogene","volume":"64","author":"Tanaka","year":"1989","journal-title":"Cancer."},{"issue":"3","key":"2024100317500718400_CIT0117","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/neuonc\/noac224","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","volume":"25","author":"Choudhury","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024100317500718400_CIT0118","doi-asserted-by":"crossref","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","article-title":"Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies","volume":"8","author":"Bayley","year":"2022","journal-title":"Sci Adv."},{"issue":"3","key":"2024100317500718400_CIT0119","doi-asserted-by":"crossref","first-page":"e13132","DOI":"10.1111\/bpa.13132","article-title":"Clinical implementation of integrated molecular-morphologic risk prediction for meningioma","volume":"33","author":"Hielscher","year":"2022","journal-title":"Brain Pathol."},{"issue":"5","key":"2024100317500718400_CIT0120","first-page":"1302","article-title":"Gene expression analysis during progression of malignant meningioma compared to benign meningioma","volume":"138","author":"Maier","year":"2023","journal-title":"J Neurosurg."},{"issue":"16","key":"2024100317500718400_CIT0121","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.3390\/cancers14164008","article-title":"Matched paired primary and recurrent meningiomas points to cell-death program contributions to genomic and epigenomic instability along tumor progression","volume":"14","author":"San-Miguel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2024100317500718400_CIT0122","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-020-0932-2","article-title":"Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes","volume":"26","author":"Nassiri","year":"2020","journal-title":"Nat Med."},{"issue":"3","key":"2024100317500718400_CIT0123","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/neuonc\/noab235","article-title":"DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma","volume":"24","author":"Zuccato","year":"2022","journal-title":"Neuro Oncol"},{"issue":"12","key":"2024100317500718400_CIT0124","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/neuonc\/noac127","article-title":"Diagnostic potential of extracellular vesicles in meningioma patients","volume":"24","author":"Ricklefs","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0125","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1038\/s41467-023-41434-z","article-title":"Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas","volume":"14","author":"Herrgott","year":"2023","journal-title":"Nat Commun."},{"issue":"6","key":"2024100317500718400_CIT0126","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3171\/2011.9.FOCUS11220","article-title":"Incidental meningiomas","volume":"31","author":"Chamoun","year":"2011","journal-title":"Neurosurg Focus."},{"issue":"11","key":"2024100317500718400_CIT0127","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"key":"2024100317500718400_CIT0128","first-page":"i26","article-title":"The management of incidental meningioma: An unresolved clinical conundrum","volume":"5","author":"Islim","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"5","key":"2024100317500718400_CIT0129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0034-1543959","article-title":"Will an asymptomatic meningioma grow or not grow? A meta-analysis","volume":"76","author":"Zeng","year":"2015","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"issue":"1","key":"2024100317500718400_CIT0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13244-019-0697-7","article-title":"Dural masses: meningiomas and their mimics","volume":"10","author":"Lyndon","year":"2019","journal-title":"Insights Imaging"},{"issue":"6","key":"2024100317500718400_CIT0131","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1215\/15228517-2008-109","article-title":"Secretory meningiomas: A benign subgroup causing life-threatening complications","volume":"11","author":"Regelsberger","year":"2009","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024100317500718400_CIT0132","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","article-title":"Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations","volume":"125","author":"Reuss","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2024100317500718400_CIT0133","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.crad.2006.09.009","article-title":"Atypical imaging appearances of intracranial meningiomas","volume":"62","author":"O\u2019Leary","year":"2007","journal-title":"Clin Radiol."},{"issue":"7","key":"2024100317500718400_CIT0134","first-page":"1514","article-title":"The dural tail sign revisited","volume":"16","author":"Bourekas","year":"1995","journal-title":"AJNR Am J Neuroradiol."},{"issue":"6","key":"2024100317500718400_CIT0135","doi-asserted-by":"crossref","first-page":"e832","DOI":"10.1016\/j.wneu.2014.07.002","article-title":"Can excision of meningiomas be limited to resection of tumor and radiologically abnormal dura mater? Neuronavigation-guided biopsies of dural tail and seemingly normal dura mater, with a review of the literature","volume":"82","author":"Slot","year":"2014","journal-title":"World Neurosurg"},{"issue":"5","key":"2024100317500718400_CIT0136","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4329\/wjr.v2.i5.188","article-title":"A review on dural tail sign","volume":"2","author":"Sotoudeh","year":"2010","journal-title":"World J Radiol"},{"issue":"1","key":"2024100317500718400_CIT0137","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1148\/radiol.2331021332","article-title":"The dural tail sign","volume":"233","author":"Wallace","year":"2004","journal-title":"Radiology."},{"issue":"12","key":"2024100317500718400_CIT0138","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00701-014-2216-4","article-title":"Immunohistochemical profile of the dural tail in intracranial meningiomas","volume":"156","author":"Wen","year":"2014","journal-title":"Acta Neurochir (Wien)."},{"issue":"3","key":"2024100317500718400_CIT0139","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11060-018-2996-0","article-title":"Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: A retrospective cohort study of 741 patients","volume":"140","author":"Wirsching","year":"2018","journal-title":"J Neurooncol."},{"issue":"4","key":"2024100317500718400_CIT0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diii.2016.08.006","article-title":"Preoperative embolization of meningiomas with polyvinyl alcohol particles: The benefits are not outweighed by risks","volume":"98","author":"Iacobucci","year":"2017","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"2024100317500718400_CIT0141","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: Report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024100317500718400_CIT0142","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s43441-022-00494-x","article-title":"Efficacy endpoints in phase II clinical trials for meningioma: An analysis of recent clinical trials","volume":"57","author":"Watanabe","year":"2023","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"2024100317500718400_CIT0143","first-page":"234","article-title":"Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024100317500718400_CIT0144","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: A RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"issue":"7","key":"2024100317500718400_CIT0145","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol."},{"issue":"11","key":"2024100317500718400_CIT0146","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"key":"2024100317500718400_CIT0147","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.wneu.2021.06.080","article-title":"The effect of radiation on meningioma volume change","volume":"153","author":"Hall","year":"2021","journal-title":"World Neurosurg"},{"issue":"1","key":"2024100317500718400_CIT0148","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.adro.2018.08.013","article-title":"Analysis of MRI volumetric changes after hypofractionated stereotactic radiation therapy for benign intracranial neoplasms","volume":"4","author":"Fega","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"2024100317500718400_CIT0149","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3171\/2014.12.JNS141341","article-title":"Quantitative tumor volumetric responses after Gamma Knife radiosurgery for meningiomas","volume":"124","author":"Harrison","year":"2016","journal-title":"J Neurosurg."},{"key":"2024100317500718400_CIT0150","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1200\/JCO.2023.41.16_suppl.2075","article-title":"3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas","volume":"41","author":"Tabouret","year":"2023","journal-title":"J Clin Oncol."},{"issue":"5","key":"2024100317500718400_CIT0151","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/neuonc\/noab259","article-title":"Consensus core clinical data elements for meningiomas (v2021.1)","volume":"24","author":"Nassiri","year":"2022","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024100317500718400_CIT0152","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ijrobp.2022.04.041","article-title":"(68)Ga-DOTATATE PET: The future of meningioma treatment","volume":"113","author":"Prasad","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"12","key":"2024100317500718400_CIT0153","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","article-title":"PET imaging in patients with meningioma-report of the RANO\/PET Group","volume":"19","author":"Galldiks","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024100317500718400_CIT0154","first-page":"jnmt.122.263949","article-title":"The complementary role of (68)Ga-DOTATATE PET\/CT in diagnosis of recurrent meningioma","author":"Kong","year":"2022","journal-title":"J Nucl Med Technol."},{"issue":"9","key":"2024100317500718400_CIT0155","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","article-title":"Detection of cranial meningiomas: Comparison of \u2076\u2078Ga-DOTATOC PET\/CT and contrast-enhanced MRI","volume":"39","author":"Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024100317500718400_CIT0156","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J Nucl Med."},{"issue":"4","key":"2024100317500718400_CIT0157","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ijrobp.2022.04.009","article-title":"(68)Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma","volume":"113","author":"Perlow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"2024100317500718400_CIT0158","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00259-019-04591-2","article-title":"Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome","volume":"47","author":"Kessel","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2024100317500718400_CIT0159","first-page":"vdab012","article-title":"[68Ga]-DOTATATE PET\/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas","volume":"3","author":"Mahase","year":"2021","journal-title":"Neurooncol. Adv.."},{"issue":"1","key":"2024100317500718400_CIT0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13014-021-01875-6","article-title":"(68)Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas","volume":"16","author":"Kowalski","year":"2021","journal-title":"Radiat Oncol."},{"issue":"1","key":"2024100317500718400_CIT0161","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/neuros\/nyaa333","article-title":"Simpson grade revisited\u2013intraoperative estimation of the extent of resection in meningiomas versus postoperative somatostatin receptor positron emission tomography\/computed tomography and magnetic resonance imaging","volume":"88","author":"Ueberschaer","year":"2021","journal-title":"Neurosurgery."},{"issue":"1","key":"2024100317500718400_CIT0162","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00259-023-06400-3","article-title":"Postoperative [(68)Ga]Ga-DOTA-TATE PET\/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1","volume":"51","author":"Teske","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"11","key":"2024100317500718400_CIT0163","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","article-title":"Next-generation PET\/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE","volume":"50","author":"Unterrainer","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2024100317500718400_CIT0164","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41181-022-00176-x","article-title":"Favorable SSTR subtype selectivity of SiTATE: New momentum for clinical [(18)F]SiTATE PET","volume":"7","author":"W\u00e4ngler","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"7","key":"2024100317500718400_CIT0165","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3174\/ajnr.A7901","article-title":"Cost-effectiveness analysis of (68)Ga-DOTATATE PET\/MRI in radiotherapy planning in patients with intermediate-risk meningioma","volume":"44","author":"Rodriguez","year":"2023","journal-title":"AJNR Am J Neuroradiol."},{"issue":"2","key":"2024100317500718400_CIT0166","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/neuonc\/noz160","article-title":"A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas","volume":"22","author":"Islim","year":"2020","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024100317500718400_CIT0167","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-019-03104-3","article-title":"Incidental intracranial meningiomas: A systematic review and meta-analysis of prognostic factors and outcomes","volume":"142","author":"Islim","year":"2019","journal-title":"J Neurooncol."},{"issue":"5","key":"2024100317500718400_CIT0168","doi-asserted-by":"crossref","first-page":"e043215","DOI":"10.1136\/bmjopen-2020-043215","article-title":"Scanxiety: A scoping review about scan-associated anxiety","volume":"11","author":"Bui","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"2024100317500718400_CIT0169","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jnnp.68.1.25","article-title":"Natural history of elderly patients with asymptomatic meningiomas","volume":"68","author":"Niiro","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"6","key":"2024100317500718400_CIT0170","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/WNL.51.6.1718","article-title":"The natural history of asymptomatic meningiomas in Olmsted County, Minnesota","volume":"51","author":"Go","year":"1998","journal-title":"Neurology."},{"issue":"1","key":"2024100317500718400_CIT0171","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1227\/01.NEU.0000068730.76856.58","article-title":"The natural history of incidental meningiomas","volume":"53","author":"Nakamura","year":"2003","journal-title":"Neurosurgery."},{"issue":"2","key":"2024100317500718400_CIT0172","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-010-0319-1","article-title":"Growth curve analysis of asymptomatic and symptomatic meningiomas","volume":"102","author":"Nakasu","year":"2011","journal-title":"J Neurooncol."},{"issue":"5","key":"2024100317500718400_CIT0173","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3171\/2017.12.JNS171943","article-title":"Clinical and radiological outcomes of proactive Gamma Knife surgery for asymptomatic meningiomas compared with the natural course without intervention","volume":"130","author":"Kim","year":"2018","journal-title":"J Neurosurg."},{"issue":"8","key":"2024100317500718400_CIT0174","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00701-018-3554-4","article-title":"Non-operative meningiomas: Long-term follow-up of 136 patients","volume":"160","author":"Romani","year":"2018","journal-title":"Acta Neurochir (Wien)."},{"key":"2024100317500718400_CIT0175","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","article-title":"Molecular and translational advances in meningiomas","volume":"21","author":"Suppiah","year":"2019","journal-title":"Neuro-Oncology."},{"issue":"5","key":"2024100317500718400_CIT0176","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3171\/2016.9.JNS161669","article-title":"A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas","volume":"127","author":"Lee","year":"2017","journal-title":"J Neurosurg."},{"key":"2024100317500718400_CIT0177","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1016\/j.wneu.2020.03.060","article-title":"Treatment outcomes of incidental intracranial meningiomas: Results from the IMPACT Cohort","volume":"138","author":"Islim","year":"2020","journal-title":"World Neurosurg"},{"issue":"1","key":"2024100317500718400_CIT0178","doi-asserted-by":"crossref","first-page":"e052705","DOI":"10.1136\/bmjopen-2021-052705","article-title":"External validation and recalibration of an incidental meningioma prognostic model - IMPACT: Protocol for an international multicentre retrospective cohort study","volume":"12","author":"Islim","year":"2022","journal-title":"BMJ Open"},{"issue":"12","key":"2024100317500718400_CIT0179","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00701-006-0909-z","article-title":"Morbidity in 201 patients with small sized meningioma treated by microsurgery","volume":"148","author":"Reinert","year":"2006","journal-title":"Acta Neurochir (Wien)."},{"issue":"9","key":"2024100317500718400_CIT0180","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00701-020-04244-6","article-title":"Indications and outcome in surgically treated asymptomatic meningiomas: A single-center case-control study","volume":"162","author":"N\u00e4slund","year":"2020","journal-title":"Acta Neurochir (Wien)."},{"issue":"1","key":"2024100317500718400_CIT0181","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/noab132","article-title":"An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: The IMPASSE study","volume":"24","author":"Sheehan","year":"2022","journal-title":"Neuro Oncol"},{"issue":"11","key":"2024100317500718400_CIT0182","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/brain\/awaa267","article-title":"PET imaging of meningioma with 18F-FLT: A predictor of tumour progression","volume":"143","author":"Bashir","year":"2020","journal-title":"Brain."},{"issue":"12","key":"2024100317500718400_CIT0183","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.3390\/cancers12123503","article-title":"Psychological burden in meningioma patients under a wait-and-watch strategy and after complete resection Is high\u2014results of a prospective single center study","volume":"12","author":"Kalasauskas","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"2024100317500718400_CIT0184","first-page":"507","article-title":"Mental health disorders in patients with untreated meningiomas: An observational cohort study using the nationwide MarketScan database","volume":"7","author":"Maurer","year":"2020","journal-title":"Neurooncol. Pract.."},{"issue":"1","key":"2024100317500718400_CIT0185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"2024100317500718400_CIT0186","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3171\/2015.9.JNS15754","article-title":"The Simpson grading revisited: Aggressive surgery and its place in modern meningioma management","volume":"125","author":"Gousias","year":"2016","journal-title":"J Neurosurg."},{"issue":"1","key":"2024100317500718400_CIT0187","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3171\/2016.1.JNS151842","article-title":"Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma","volume":"126","author":"Nanda","year":"2017","journal-title":"J Neurosurg."},{"issue":"4","key":"2024100317500718400_CIT0188","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s10143-020-01428-7","article-title":"The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy","volume":"44","author":"Behling","year":"2021","journal-title":"Neurosurg Rev."},{"key":"2024100317500718400_CIT0189","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clineuro.2016.01.006","article-title":"WHO grade 1 meningioma recurrence: Are location and Simpson grade still relevant","volume":"141","author":"Gallagher","year":"2016","journal-title":"Clin Neurol Neurosurg."},{"issue":"2","key":"2024100317500718400_CIT0190","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3171\/2020.6.JNS201904","article-title":"The Simpson grade: Abandon the scale but preserve the message","volume":"135","author":"Schwartz","year":"2020","journal-title":"J Neurosurg."},{"issue":"5","key":"2024100317500718400_CIT0191","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3171\/2010.3.JNS091971","article-title":"The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas","volume":"113","author":"Sughrue","year":"2010","journal-title":"J Neurosurg."},{"issue":"2","key":"2024100317500718400_CIT0192","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3171\/2015.7.JNS15546","article-title":"Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas","volume":"125","author":"Mansouri","year":"2016","journal-title":"J Neurosurg."},{"issue":"1","key":"2024100317500718400_CIT0193","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1038\/s41598-020-65365-7","article-title":"Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity","volume":"10","author":"Zador","year":"2020","journal-title":"Sci Rep."},{"issue":"5","key":"2024100317500718400_CIT0194","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3171\/2009.9.JNS09617","article-title":"A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas","volume":"112","author":"McGovern","year":"2010","journal-title":"J Neurosurg."},{"issue":"3","key":"2024100317500718400_CIT0195","first-page":"394","article-title":"Grade zero removal of supratentorial convexity meningiomas","volume":"33","author":"Kinjo","year":"1993","journal-title":"Neurosurgery."},{"issue":"8","key":"2024100317500718400_CIT0196","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3390\/cancers14082007","article-title":"The Simpson grading: Is it still valid","volume":"14","author":"Chotai","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2024100317500718400_CIT0197","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3171\/2012.6.JNS111987","article-title":"A radiopathological classification of dural tail sign of meningiomas","volume":"117","author":"Qi","year":"2012","journal-title":"J Neurosurg."},{"issue":"24","key":"2024100317500718400_CIT0198","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1021\/ac0512599","article-title":"Detection of meningioma in dura mater by Raman spectroscopy","volume":"77","author":"Koljenovi\u0107","year":"2005","journal-title":"Anal Chem."},{"key":"2024100317500718400_CIT0199","doi-asserted-by":"crossref","first-page":"979940","DOI":"10.3389\/fsurg.2022.979940","article-title":"Surgical management of tuberculum sellae meningioma: Transcranial approach or endoscopic endonasal approach","volume":"9","author":"Qian","year":"2022","journal-title":"Front Surg"},{"issue":"5\u20136","key":"2024100317500718400_CIT0200","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.wneu.2011.08.025","article-title":"Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas","volume":"77","author":"Komotar","year":"2012","journal-title":"World Neurosurg"},{"issue":"3","key":"2024100317500718400_CIT0201","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1227\/neu.0000000000002569","article-title":"International Tuberculum Sellae Meningioma Study: Surgical outcomes and management trends","volume":"96","author":"Magill","year":"2023","journal-title":"Neurosurgery."},{"issue":"1","key":"2024100317500718400_CIT0202","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","article-title":"Intermediate-risk meningioma: Initial outcomes from NRG Oncology RTOG 0539","volume":"129","author":"Rogers","year":"2018","journal-title":"J Neurosurg."},{"issue":"4","key":"2024100317500718400_CIT0203","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.11.028","article-title":"High-risk meningioma: Initial outcomes from NRG Oncology\/RTOG 0539","volume":"106","author":"Rogers","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"2024100317500718400_CIT0204","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.radonc.2018.06.018","article-title":"Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042)","volume":"128","author":"Weber","year":"2018","journal-title":"Radiother Oncol."},{"issue":"4","key":"2024100317500718400_CIT0205","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/neuonc\/noad244","article-title":"Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial","volume":"26","author":"Deng","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024100317500718400_CIT0206","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ijrobp.2023.09.026","article-title":"Dose-escalated radiation therapy is associated with improved outcomes for high-grade meningioma","volume":"118","author":"Zeng","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"2024100317500718400_CIT0207","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-022-04171-9","article-title":"Radiotherapy for meningiomas","volume":"160","author":"Chen","year":"2022","journal-title":"J Neurooncol."},{"key":"2024100317500718400_CIT0208","first-page":"i67","article-title":"Radiotherapy and radiosurgery for meningiomas","volume":"5","author":"Chen","year":"2023","journal-title":"Neurooncol. Adv.."},{"key":"2024100317500718400_CIT0209","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s13063-015-1040-3","article-title":"The ROAM\/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: Study protocol for a randomised controlled trial","volume":"16","author":"Jenkinson","year":"2015","journal-title":"Trials"},{"issue":"11","key":"2024100317500718400_CIT0210","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/neuonc\/nou149","article-title":"Radiotherapy versus observation following surgical resection of atypical meningioma (the ROAM trial)","volume":"16","author":"Jenkinson","year":"2014","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/tcr.2018.10.07","article-title":"A management dilemma: Adjuvant radiotherapy after gross total resection of atypical meningioma","volume":"8","author":"Fleming","year":"2019","journal-title":"Transl Cancer Res"},{"key":"2024100317500718400_CIT0212","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-030-64508-3_3","article-title":"Atypical and Malignant Meningioma","author":"Okoye","year":"2021","journal-title":"Intracranial Spinal Radiother"},{"issue":"6","key":"2024100317500718400_CIT0213","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2024100317500718400_CIT0214","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2024100317500718400_CIT0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","article-title":"The WHO classification of tumors of the nervous system","volume":"61","author":"Kleihues","year":"2002","journal-title":"J Neuropathol Exp Neurol."},{"key":"2024100317500718400_CIT0216","first-page":"2","article-title":"The definition and role of brain invasion in meningioma grading: Still controversial after all these years","volume":"2","author":"Perry","year":"2021","journal-title":"Free Neuropathol"},{"issue":"4","key":"2024100317500718400_CIT0217","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00428-020-02988-1","article-title":"The histopathological diagnosis of atypical meningioma: Glass slide versus whole slide imaging for grading assessment","volume":"478","author":"Ammendola","year":"2021","journal-title":"Virchows Arch."},{"issue":"6","key":"2024100317500718400_CIT0218","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00401-023-02642-5","article-title":"Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: Comprehensive molecular analysis of EORTC 22042-26042","volume":"146","author":"Maas","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2024100317500718400_CIT0219","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med."},{"issue":"2","key":"2024100317500718400_CIT0220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/neuonc\/noad212","article-title":"A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses","volume":"26","author":"Raleigh","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0221","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1971400917744885","article-title":"Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment","volume":"31","author":"Di Franco","year":"2018","journal-title":"Neuroradiol J"},{"issue":"4","key":"2024100317500718400_CIT0222","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.otc.2009.04.010","article-title":"Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas","volume":"42","author":"McGregor","year":"2009","journal-title":"Otolaryngol Clin North Am."},{"key":"2024100317500718400_CIT0223","first-page":"100631","article-title":"Outcomes and predictors of response to fractionated radiotherapy as primary treatment for intracranial meningiomas","volume":"41","author":"Wang","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"2024100317500718400_CIT0224","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-016-2121-1","article-title":"Parameters influencing local control of meningiomas treated with radiosurgery","volume":"128","author":"Kaprealian","year":"2016","journal-title":"J Neurooncol."},{"issue":"4","key":"2024100317500718400_CIT0225","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jjco\/hyq231","article-title":"Long-term outcomes of fractionated stereotactic radiotherapy for intracranial skull base benign meningiomas in single institution","volume":"41","author":"Onodera","year":"2011","journal-title":"Jpn J Clin Oncol."},{"issue":"1","key":"2024100317500718400_CIT0226","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuchi.2014.10.112","article-title":"Fractionated radiotherapy and radiosurgery of intracranial meningiomas","volume":"64","author":"Biau","year":"2018","journal-title":"Neurochirurgie."},{"issue":"4","key":"2024100317500718400_CIT0227","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1055\/a-0828-7335","article-title":"Visual outcomes of fractionated radiotherapy in optic nerve sheath meningioma: A Retrospective Study","volume":"236","author":"Kheir","year":"2019","journal-title":"Klin Monbl Augenheilkd"},{"issue":"5","key":"2024100317500718400_CIT0228","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/bjo.2009.167346","article-title":"Long-term response to fractionated radiotherapy of presumed optic nerve sheath meningioma","volume":"94","author":"Lesser","year":"2010","journal-title":"Br J Ophthalmol."},{"issue":"5","key":"2024100317500718400_CIT0229","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/neuros\/nyaa169","article-title":"Stereotactic radiosurgery for intracranial noncavernous sinus benign meningioma: International stereotactic radiosurgery society systematic review, meta-analysis and practice guideline","volume":"87","author":"Marchetti","year":"2020","journal-title":"Neurosurgery."},{"issue":"5","key":"2024100317500718400_CIT0230","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ijrobp.2004.05.073","article-title":"Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas","volume":"60","author":"DiBiase","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2024100317500718400_CIT0231","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5607\/en.2018.27.3.245","article-title":"Fractionated gamma knife radiosurgery as initial treatment for large skull base meningioma","volume":"27","author":"Park","year":"2018","journal-title":"Exp Neurobiol"},{"issue":"5","key":"2024100317500718400_CIT0232","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3171\/2014.12.JNS142159","article-title":"Edema following gamma knife radiosurgery for parasagittal and parafalcine meningiomas","volume":"123","author":"Sheehan","year":"2015","journal-title":"J Neurosurg."},{"issue":"1","key":"2024100317500718400_CIT0233","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1227\/01.NEU.0000311061.72626.0D","article-title":"Radiosurgery as definitive management of intracranial meningiomas","volume":"62","author":"Kondziolka","year":"2008","journal-title":"Neurosurgery."},{"issue":"3","key":"2024100317500718400_CIT0234","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ijrobp.2021.01.048","article-title":"Treatment of WHO Grade 2 meningiomas with stereotactic radiosurgery: Identification of an optimal group for SRS using RPA","volume":"110","author":"Kowalchuk","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"4","key":"2024100317500718400_CIT0235","doi-asserted-by":"crossref","first-page":"e220157","DOI":"10.1148\/rycan.220157","article-title":"A review of theranostics: Perspectives on emerging approaches and clinical advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol Imaging Cancer"},{"issue":"5","key":"2024100317500718400_CIT0236","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.122.264586","article-title":"(64)Cu treatment planning and (67)Cu therapy with radiolabeled [(64)Cu\/(67)Cu]MeCOSar-octreotate in subjects with unresectable multifocal meningioma: Initial results for human imaging, safety, biodistribution, and radiation dosimetry","volume":"64","author":"Bailey","year":"2023","journal-title":"J Nucl Med."},{"issue":"4","key":"2024100317500718400_CIT0237","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med."},{"issue":"10","key":"2024100317500718400_CIT0238","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1007\/s00330-023-09697-8","article-title":"Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy","volume":"33","author":"Boursier","year":"2023","journal-title":"Eur Radiol."},{"issue":"2","key":"2024100317500718400_CIT0239","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"2024100317500718400_CIT0240","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","article-title":"Lutathera(\u00ae) Orphans: State of the art and future application of radioligand therapy with (177)Lu-DOTATATE","volume":"15","author":"Urso","year":"2023","journal-title":"Pharmaceutics"},{"key":"2024100317500718400_CIT0241","doi-asserted-by":"crossref","first-page":"vii85","DOI":"10.1093\/neuonc\/noac209.322","article-title":"CTNI-57. Radionuclide therapy with 177Lu-DOTATATE (Lutathera) in adults with advanced intracranial meningioma- interim results of a single-arm open-label multicenter phase II study multicenter study","volume":"24","author":"Kurz","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"2","key":"2024100317500718400_CIT0242","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-022-04148-8","article-title":"Emerging systemic treatment options in meningioma","volume":"161","author":"Mair","year":"2023","journal-title":"J Neurooncol."},{"issue":"1","key":"2024100317500718400_CIT0243","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0244","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J Neurooncol."},{"issue":"1","key":"2024100317500718400_CIT0245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J Neurooncol."},{"issue":"2","key":"2024100317500718400_CIT0246","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J Neurooncol."},{"issue":"5","key":"2024100317500718400_CIT0247","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/neuonc\/noab243","article-title":"Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)","volume":"24","author":"Preusser","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0248","first-page":"vdac123","article-title":"A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma","volume":"4","author":"Kumthekar","year":"2022","journal-title":"Neurooncol. Adv.."},{"issue":"2","key":"2024100317500718400_CIT0249","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J Neurooncol."},{"issue":"3","key":"2024100317500718400_CIT0250","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","article-title":"Salvage chemotherapy with CPT-11 for recurrent meningioma","volume":"78","author":"Chamberlain","year":"2006","journal-title":"J Neurooncol."},{"issue":"1","key":"2024100317500718400_CIT0251","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12885-022-09340-7","article-title":"Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: A retrospective chart review","volume":"22","author":"Belanger","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"2024100317500718400_CIT0252","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3171\/jns.1996.84.5.0733","article-title":"Adjuvant combined modality therapy for malignant meningiomas","volume":"84","author":"Chamberlain","year":"1996","journal-title":"J Neurosurg."},{"issue":"3","key":"2024100317500718400_CIT0253","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology."},{"issue":"5","key":"2024100317500718400_CIT0254","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00280-014-2422-z","article-title":"Recurrent high-grade meningioma: A phase II trial with somatostatin analogue therapy","volume":"73","author":"Sim\u00f3","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"2024100317500718400_CIT0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: lLong-term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med."},{"issue":"3","key":"2024100317500718400_CIT0256","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: Results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res."},{"key":"2024100317500718400_CIT0257","doi-asserted-by":"crossref","first-page":"267831","DOI":"10.1155\/2015\/267831","article-title":"The role of mifepristone in meningiomas management: A systematic review of the literature","volume":"2015","author":"Cossu","year":"2015","journal-title":"Biomed Res Int."},{"issue":"7","key":"2024100317500718400_CIT0258","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.18632\/oncotarget.3082","article-title":"Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma","volume":"6","author":"Du","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2024100317500718400_CIT0259","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat Commun."},{"issue":"1","key":"2024100317500718400_CIT0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7","key":"2024100317500718400_CIT0261","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology."},{"issue":"6","key":"2024100317500718400_CIT0262","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024100317500718400_CIT0263","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J Neurooncol."},{"issue":"2","key":"2024100317500718400_CIT0264","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec\u00ae plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J Neurooncol."},{"issue":"34","key":"2024100317500718400_CIT0265","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005","volume":"33","author":"Ji","year":"2015","journal-title":"J Clin Oncol."},{"key":"2024100317500718400_CIT0266","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.wneu.2015.09.060","article-title":"Combined hydroxyurea and verapamil in the clinical treatment of refractory meningioma: Human and Orthotopic Xenograft Studies","volume":"86","author":"Karsy","year":"2016","journal-title":"World Neurosurg"},{"issue":"3","key":"2024100317500718400_CIT0267","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: Phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024100317500718400_CIT0268","first-page":"vdad041","article-title":"Prospective phase II trial of the dual mTORC1\/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2","volume":"5","author":"Jordan","year":"2023","journal-title":"Neurooncol. Adv.."},{"key":"2024100317500718400_CIT0269","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajp.2019.03.029","article-title":"Meningioma and psychiatric symptoms: An individual patient data analysis","volume":"42","author":"Gyawali","year":"2019","journal-title":"Asian J Psychiatr"},{"key":"2024100317500718400_CIT0270","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.wneu.2017.12.012","article-title":"Presenting symptoms and prognostic factors for symptomatic outcomes following resection of meningioma","volume":"111","author":"Wu","year":"2018","journal-title":"World Neurosurg"},{"key":"2024100317500718400_CIT0271","doi-asserted-by":"crossref","first-page":"i32","DOI":"10.1093\/neuonc\/noy152","article-title":"Life after surgical resection of a meningioma: A prospective cross-sectional study evaluating health-related quality of life","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0272","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-012-0947-8","article-title":"The influence of surgery on quality of life in patients with intracranial meningiomas: A prospective study","volume":"110","author":"Jakola","year":"2012","journal-title":"J Neurooncol."},{"issue":"4","key":"2024100317500718400_CIT0273","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jocn.2009.07.111","article-title":"A multivariate analysis of prognostic factors for health-related quality of life in patients with surgically managed meningioma","volume":"17","author":"Miao","year":"2010","journal-title":"J Clin Neurosci."},{"issue":"7","key":"2024100317500718400_CIT0274","first-page":"897","article-title":"Impaired health-related quality of life in meningioma patients-a systematic review","volume":"19","author":"Zamanipoor Najafabadi","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0275","first-page":"vdaa086","article-title":"How to live with a meningioma: Experiences, symptoms, and challenges reported by patients","volume":"2","author":"Nassiri","year":"2020","journal-title":"Neurooncol. Adv.."},{"issue":"1","key":"2024100317500718400_CIT0276","first-page":"vdab089","article-title":"Health-related quality of life in meningioma","volume":"3","author":"Haider","year":"2021","journal-title":"Neurooncol. Adv.."},{"issue":"3","key":"2024100317500718400_CIT0277","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-007-9366-7","article-title":"Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients","volume":"84","author":"van Nieuwenhuizen","year":"2007","journal-title":"J Neurooncol."},{"issue":"1","key":"2024100317500718400_CIT0278","doi-asserted-by":"crossref","first-page":"19730","DOI":"10.1038\/s41598-022-24192-8","article-title":"Health-related quality of life and clinical outcome after radiotherapy of patients with intracranial meningioma","volume":"12","author":"Lisowski","year":"2022","journal-title":"Sci Rep."},{"issue":"1","key":"2024100317500718400_CIT0279","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-013-1099-1","article-title":"Quality of life after stereotactic radiotherapy for meningioma: A prospective non-randomized study","volume":"113","author":"Henzel","year":"2013","journal-title":"J Neurooncol."},{"issue":"2","key":"2024100317500718400_CIT0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/neuros\/nyx001","article-title":"Factors associated with pre- and postoperative seizures in 1033 patients undergoing supratentorial meningioma resection","volume":"81","author":"Chen","year":"2017","journal-title":"Neurosurgery."},{"issue":"6","key":"2024100317500718400_CIT0281","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3171\/2015.4.JNS142742","article-title":"Seizures in supratentorial meningioma: A systematic review and meta-analysis","volume":"124","author":"Englot","year":"2016","journal-title":"J Neurosurg."},{"issue":"3","key":"2024100317500718400_CIT0282","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3171\/2020.7.JNS201042","article-title":"Clinical and genomic factors associated with seizures in meningiomas","volume":"135","author":"Gupte","year":"2020","journal-title":"J Neurosurg."},{"key":"2024100317500718400_CIT0283","doi-asserted-by":"crossref","first-page":"905976","DOI":"10.3389\/fonc.2022.905976","article-title":"Meningioma related epilepsy- pathophysiology, pre\/postoperative seizures predicators and treatment","volume":"12","author":"Elbadry Ahmed","year":"2022","journal-title":"Front Oncol."},{"key":"2024100317500718400_CIT0284","first-page":"i49","article-title":"The clinical and genomic features of seizures in meningiomas","volume":"5","author":"Dincer","year":"2023","journal-title":"Neurooncol. Adv."},{"issue":"8","key":"2024100317500718400_CIT0285","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2176\/nmc.36.568","article-title":"Peritumoral edema and seizure in patients with cerebral convexity and parasagittal meningiomas","volume":"36","author":"Kawaguchi","year":"1996","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"2","key":"2024100317500718400_CIT0286","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3171\/jns.1992.77.2.0209","article-title":"Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas","volume":"77","author":"Haglund","year":"1992","journal-title":"J Neurosurg."},{"issue":"5","key":"2024100317500718400_CIT0287","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/BF01411166","article-title":"Brain oedema in patients with intracranial meningioma. Correlation between clinical, radiological, and histological factors and the presence and intensity of oedema","volume":"138","author":"Lobato","year":"1996","journal-title":"Acta Neurochir (Wien)."},{"key":"2024100317500718400_CIT0288","first-page":"ii58","article-title":"Clinical management of seizures in patients with meningiomas: Efficacy of surgical resection for seizure control and patient-tailored postoperative anti-epileptic drug management","volume":"5","author":"Peart","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"1","key":"2024100317500718400_CIT0289","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/noad154","article-title":"Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management","volume":"26","author":"Avila","year":"2023","journal-title":"Neuro Oncol"},{"key":"2024100317500718400_CIT0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jocn.2017.05.020","article-title":"The role of prophylactic antiepileptic drugs for seizure prophylaxis in meningioma surgery: A systematic review","volume":"43","author":"Islim","year":"2017","journal-title":"J Clin Neurosci."},{"issue":"1","key":"2024100317500718400_CIT0291","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0920-1211(99)00066-2","article-title":"Intracranial meningiomas and epilepsy: Incidence, prognosis and influencing factors","volume":"38","author":"Lieu","year":"2000","journal-title":"Epilepsy Res."},{"key":"2024100317500718400_CIT0292","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.wneu.2016.10.062","article-title":"Risk factors of preoperative and early postoperative seizures in patients with meningioma: A Retrospective Single-Center Cohort Study","volume":"97","author":"Skardelly","year":"2017","journal-title":"World Neurosurg"},{"issue":"3","key":"2024100317500718400_CIT0293","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3171\/2010.5.JNS091972","article-title":"Postoperative seizures following the resection of convexity meningiomas: Are prophylactic anticonvulsants indicated? Clinical article","volume":"114","author":"Sughrue","year":"2011","journal-title":"J Neurosurg."},{"issue":"1","key":"2024100317500718400_CIT0294","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-018-2941-2","article-title":"Postoperative seizures in meningioma patients: Improving patient selection for antiepileptic drug therapy","volume":"140","author":"Islim","year":"2018","journal-title":"J Neurooncol."},{"key":"2024100317500718400_CIT0295","doi-asserted-by":"crossref","first-page":"ii195","DOI":"10.1093\/neuonc\/noaa215.815","article-title":"RTID-10. Surgeons trial of prophylaxis for epilepsy in seizure na\u00efve patients with meningioma: A randomized controlled trial (STOP \u2018EM)","volume":"22","author":"Jenkinson","year":"2020","journal-title":"Neuro-Oncology."},{"issue":"12","key":"2024100317500718400_CIT0296","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/jmg.29.12.841","article-title":"A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity","volume":"29","author":"Evans","year":"1992","journal-title":"J Med Genet."},{"issue":"1","key":"2024100317500718400_CIT0297","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol."},{"key":"2024100317500718400_CIT0298","first-page":"ii94","article-title":"The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis","volume":"5","author":"Gregory","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"5","key":"2024100317500718400_CIT0299","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/00006123-199605000-00004","article-title":"The neuroimaging and clinical spectrum of neurofibromatosis 2","volume":"38","author":"Mautner","year":"1996","journal-title":"Neurosurgery."},{"issue":"6","key":"2024100317500718400_CIT0300","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1227\/neu.0000000000001926","article-title":"Multiple meningiomas as a criterion for the diagnosis of neurofibromatosis type 2 and other tumor predisposition syndromes","volume":"90","author":"Hannan","year":"2022","journal-title":"Neurosurgery."},{"issue":"5","key":"2024100317500718400_CIT0301","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3171\/2020.3.JNS192382","article-title":"Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients","volume":"134","author":"Abi Jaoude","year":"2020","journal-title":"J Neurosurg."},{"issue":"8","key":"2024100317500718400_CIT0302","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/neuonc\/nos129","article-title":"Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: Clinical, radiological, and molecular features","volume":"14","author":"Goutagny","year":"2012","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024100317500718400_CIT0303","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.wneu.2015.05.068","article-title":"3D volumetric measurement of neurofibromatosis type 2-associated meningiomas: Association between tumor location and growth rate","volume":"84","author":"Evers","year":"2015","journal-title":"World Neurosurg"},{"issue":"7","key":"2024100317500718400_CIT0304","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/neuonc\/noaa284","article-title":"Disease course of neurofibromatosis type 2: A 30-year follow-up study of 353 patients seen at a single institution","volume":"23","author":"Forde","year":"2021","journal-title":"Neuro Oncol"},{"key":"2024100317500718400_CIT0305","doi-asserted-by":"crossref","first-page":"e929","DOI":"10.1016\/j.wneu.2019.01.211","article-title":"Efficacy and safety of gamma knife radiosurgery for meningiomas in patients with neurofibromatosis type 2: A long-term Follow-Up Single-Center Study","volume":"125","author":"Gao","year":"2019","journal-title":"World Neurosurg"},{"issue":"1","key":"2024100317500718400_CIT0306","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3171\/2020.12.JNS202814","article-title":"Neurofibromatosis type 2-associated meningiomas: An international multicenter study of outcomes after Gamma Knife stereotactic radiosurgery","volume":"136","author":"Mohammed","year":"2022","journal-title":"J Neurosurg."},{"issue":"3","key":"2024100317500718400_CIT0307","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11060-016-2257-z","article-title":"Gamma Knife radiosurgery for neurofibromatosis type 2-associated meningiomas: A 22-year patient series","volume":"130","author":"Birckhead","year":"2016","journal-title":"J Neurooncol."},{"issue":"3","key":"2024100317500718400_CIT0308","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3171\/2014.10.JNS132593","article-title":"Gamma Knife radiosurgery for meningiomas in patients with neurofibromatosis Type 2","volume":"122","author":"Liu","year":"2015","journal-title":"J Neurosurg."},{"issue":"1","key":"2024100317500718400_CIT0309","first-page":"vdad025","article-title":"Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy\/malignant progression","volume":"5","author":"Evans","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"5","key":"2024100317500718400_CIT0310","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","article-title":"Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2","volume":"261","author":"Ferner","year":"2014","journal-title":"J Neurol."},{"issue":"4","key":"2024100317500718400_CIT0311","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0194599815573002","article-title":"Quality of Life (QoL) assessment in patients with neurofibromatosis Type 2 (NF2)","volume":"153","author":"Cosetti","year":"2015","journal-title":"Otolaryngol Head Neck Surg."},{"issue":"3","key":"2024100317500718400_CIT0312","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","article-title":"Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2","volume":"139","author":"Osorio","year":"2018","journal-title":"J Neurooncol."},{"key":"2024100317500718400_CIT0313","doi-asserted-by":"crossref","first-page":"vii88","DOI":"10.1093\/neuonc\/noac209.330","article-title":"CTNI-65. INTUITT-NF2, an adaptive platform-basket trial for neurofibromatosis 2 patients with progressive tumors: Interim results of the brigatinib treatment arm","volume":"24","author":"Plotkin","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"3","key":"2024100317500718400_CIT0314","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/neuonc\/noy124","article-title":"Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: Contributions of radiation dose, exposed cranial volume, and age","volume":"21","author":"Kok","year":"2019","journal-title":"Neuro Oncol"},{"issue":"14","key":"2024100317500718400_CIT0315","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2016.70.1896","article-title":"Morbidity and mortality associated with meningioma after cranial radiotherapy: A report from the Childhood Cancer Survivor Study","volume":"35","author":"Bowers","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2024100317500718400_CIT0316","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1667\/RR3329","article-title":"Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis","volume":"163","author":"Sadetzki","year":"2005","journal-title":"Radiat Res."},{"issue":"3","key":"2024100317500718400_CIT0317","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jjco\/hyac191","article-title":"Secondary meningioma after cranial irradiation: Case series and comprehensive literature review","volume":"53","author":"Maeda","year":"2023","journal-title":"Jpn J Clin Oncol."},{"issue":"1","key":"2024100317500718400_CIT0318","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0360-3016(00)00609-X","article-title":"Secondary intracranial meningiomas after high-dose cranial irradiation: Report of five cases and review of the literature","volume":"48","author":"Strojan","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"2024100317500718400_CIT0319","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0165-4608(95)00064-V","article-title":"Allelic status of chromosome 1 in neoplasms of the nervous system","volume":"83","author":"Bello","year":"1995","journal-title":"Cancer Genet Cytogenet."},{"issue":"12","key":"2024100317500718400_CIT0320","doi-asserted-by":"crossref","first-page":"109916","DOI":"10.1016\/j.radonc.2023.109916","article-title":"Favourable outcomes with an initial active surveillance strategy for asymptomatic radiation-induced meningiomas in long-term survivors of paediatric and young adult malignancies","volume":"189","author":"Xu","year":"2023","journal-title":"Radiother Oncol."},{"issue":"1","key":"2024100317500718400_CIT0321","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2004.09.033","article-title":"Gamma knife radiosurgery of radiation-induced intracranial tumors: Local control, outcomes, and complications","volume":"62","author":"Jensen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2024100317500718400_CIT0322","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3171\/2020.7.JNS202064","article-title":"Stereotactic radiosurgery for treatment of radiation-induced meningiomas: A multiinstitutional study","volume":"135","author":"Bunevicius","year":"2021","journal-title":"J Neurosurg."},{"issue":"3","key":"2024100317500718400_CIT0323","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1227\/01.NEU.0000336765.85922.D9","article-title":"Stereotactic radiosurgery for radiation-induced meningiomas","volume":"64","author":"Kondziolka","year":"2009","journal-title":"Neurosurgery."},{"issue":"6","key":"2024100317500718400_CIT0324","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000339636","article-title":"Gamma knife stereotactic radiosurgery for radiation-induced meningiomas","volume":"90","author":"Kuhn","year":"2012","journal-title":"Stereotact Funct Neurosurg."},{"issue":"6","key":"2024100317500718400_CIT0325","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3171\/jns.1989.71.6.0842","article-title":"Primary intraspinal neoplasms in Norway, 1955 to 1986. A population-based survey of 467 patients","volume":"71","author":"Helseth","year":"1989","journal-title":"J Neurosurg."},{"issue":"2","key":"2024100317500718400_CIT0326","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11060-023-04238-1","article-title":"A current review of spinal meningiomas: epidemiology, clinical presentation and management","volume":"161","author":"Elsamadicy","year":"2023","journal-title":"J Neurooncol."},{"issue":"1","key":"2024100317500718400_CIT0327","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.1038\/s41598-021-91225-z","article-title":"Clinical features and prognostic factors in spinal meningioma surgery from a multicenter study","volume":"11","author":"Kobayashi","year":"2021","journal-title":"Sci Rep."},{"issue":"3","key":"2024100317500718400_CIT0328","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11060-018-2993-3","article-title":"Clinical and prognostic features of spinal meningioma: A thorough analysis from a single neurosurgical center","volume":"140","author":"Hua","year":"2018","journal-title":"J Neurooncol."},{"issue":"5","key":"2024100317500718400_CIT0329","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00401-022-02474-9","article-title":"Two predominant molecular subtypes of spinal meningioma: Thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord","volume":"144","author":"Hua","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2024100317500718400_CIT0330","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00401-022-02504-6","article-title":"Genetic and epigenetic profiling identifies two distinct classes of spinal meningiomas","volume":"144","author":"Ricklefs","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2024100317500718400_CIT0331","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.jnen.0000229234.13372.d8","article-title":"Microarray-based analysis of spinal versus intracranial meningiomas: Different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression","volume":"65","author":"Sayagu\u00e9s","year":"2006","journal-title":"J Neuropathol Exp Neurol."},{"issue":"10","key":"2024100317500718400_CIT0332","doi-asserted-by":"crossref","first-page":"E617","DOI":"10.1097\/BRS.0b013e31824167f1","article-title":"Long-term surgical outcomes of spinal meningiomas","volume":"37","author":"Nakamura","year":"2012","journal-title":"Spine (Phila Pa 1976)"},{"issue":"6","key":"2024100317500718400_CIT0333","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3171\/foc.2003.14.6.1","article-title":"Avoidance of structural pitfalls in spinal meningioma resection","volume":"14","author":"Misra","year":"2003","journal-title":"Neurosurg Focus."},{"issue":"6","key":"2024100317500718400_CIT0334","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2019.3.FOCUS1969","article-title":"Trends in the utilization of radiotherapy for spinal meningiomas: Insights from the 2004-2015 National Cancer Database","volume":"46","author":"Yolcu","year":"2019","journal-title":"Neurosurg Focus."},{"issue":"1","key":"2024100317500718400_CIT0335","first-page":"4","article-title":"Stereotactic radiotherapy for spinal meningiomas and neurinomas","volume":"79","author":"Golanov","year":"2015","journal-title":"Voprosy Neirokhirurgii Imeni N.N. Burdenko"},{"issue":"1","key":"2024100317500718400_CIT0336","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7785\/tcrt.2012.500231","article-title":"Radiosurgery of spinal meningiomas and schwannomas","volume":"11","author":"Kufeld","year":"2012","journal-title":"Technol Cancer Res Treat."},{"issue":"3","key":"2024100317500718400_CIT0337","first-page":"167","article-title":"Stereotactic body radiotherapy for benign spinal tumors: Meningiomas, schwannomas, and neurofibromas","volume":"6","author":"Hwang","year":"2019","journal-title":"J Radiosurg SBRT"},{"issue":"13","key":"2024100317500718400_CIT0338","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(11)70275-3","article-title":"Meningiomas in children and adolescents: A meta-analysis of individual patient data","volume":"12","author":"Kotecha","year":"2011","journal-title":"Lancet Oncol."},{"key":"2024100317500718400_CIT0339","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"14","key":"2024100317500718400_CIT0340","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1002\/cam4.2516","article-title":"Trends in intracranial meningioma incidence in the United States, 2004-2015","volume":"8","author":"Lin","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"2024100317500718400_CIT0341","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11060-018-2756-1","article-title":"Pediatric versus adult meningioma: Comparison of epidemiology, treatments, and outcomes using the Surveillance, Epidemiology, and End Results database","volume":"137","author":"Dudley","year":"2018","journal-title":"J Neurooncol."},{"key":"2024100317500718400_CIT0342","first-page":"ii105","article-title":"Pediatric meningiomas: A literature review and diagnostic update","volume":"5","author":"Tauzi\u00e8de-Espariat","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"7","key":"2024100317500718400_CIT0343","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00381-012-1759-z","article-title":"Pediatric meningiomas in The Netherlands 1974-2010: A descriptive epidemiological case study","volume":"28","author":"Thuijs","year":"2012","journal-title":"Childs Nerv Syst."},{"issue":"5","key":"2024100317500718400_CIT0344","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00401-021-02351-x","article-title":"Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas","volume":"142","author":"Kirches","year":"2021","journal-title":"Acta Neuropathol."},{"key":"2024100317500718400_CIT0345","doi-asserted-by":"crossref","first-page":"592800","DOI":"10.3389\/fonc.2020.592800","article-title":"Clear cell meningioma in the central nervous system: Analysis of surveillance, epidemiology, and end results database","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol."},{"issue":"2","key":"2024100317500718400_CIT0346","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3171\/2011.3.JNS101748","article-title":"Treatment and survival of patients with nonmalignant intracranial meningioma: Results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article","volume":"115","author":"Cahill","year":"2011","journal-title":"J Neurosurg."},{"issue":"2","key":"2024100317500718400_CIT0347","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/02688697.2020.1726286","article-title":"Children\u2019s Cancer and Leukaemia Group (CCLG): Review and guidelines for the management of meningioma in children, teenagers and young adults","volume":"34","author":"Szychot","year":"2020","journal-title":"Br J Neurosurg."},{"issue":"8","key":"2024100317500718400_CIT0348","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00381-019-04156-6","article-title":"Management of pediatric CNS meningiomas: CCHE-57357 experience in 39 cases","volume":"35","author":"El Beltagy","year":"2019","journal-title":"Childs Nerv Syst."},{"issue":"6","key":"2024100317500718400_CIT0349","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/bpa.12884","article-title":"Pediatric meningioma: A clinicopathologic and molecular study with potential grading implications","volume":"30","author":"Toland","year":"2020","journal-title":"Brain Pathol."},{"issue":"1","key":"2024100317500718400_CIT0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2012","journal-title":"Am J Med Genet A."},{"issue":"3","key":"2024100317500718400_CIT0351","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11910-009-0034-5","article-title":"Advances in meningioma therapy","volume":"9","author":"Norden","year":"2009","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"3","key":"2024100317500718400_CIT0352","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","article-title":"Medical therapies for meningiomas","volume":"99","author":"Wen","year":"2010","journal-title":"J Neurooncol."},{"issue":"1","key":"2024100317500718400_CIT0353","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/neup.12426","article-title":"Clinicopathological and molecular characteristics of pediatric meningiomas","volume":"38","author":"Battu","year":"2018","journal-title":"Neuropathol"},{"issue":"10","key":"2024100317500718400_CIT0354","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jnen\/60.10.994","article-title":"Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: A clinicopathologic study of 53 cases","volume":"60","author":"Perry","year":"2001","journal-title":"J Neuropathol Exp Neurol."},{"issue":"1","key":"2024100317500718400_CIT0355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00401-019-02095-9","article-title":"YAP1-fusions in pediatric NF2-wildtype meningioma","volume":"139","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"13-14","key":"2024100317500718400_CIT0356","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1101\/gad.349876.122","article-title":"Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice","volume":"36","author":"Szulzewsky","year":"2022","journal-title":"Genes Dev."},{"issue":"2","key":"2024100317500718400_CIT0357","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/0008-5472.CAN-20-3857","article-title":"Human endogenous retrovirus type K promotes proliferation and confers sensitivity to antiretroviral drugs in merlin-negative schwannoma and meningioma","volume":"82","author":"Maze","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"2024100317500718400_CIT0358","first-page":"vdaa008","article-title":"Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells","volume":"2","author":"Ferluga","year":"2020","journal-title":"Neurooncol. Adv.."},{"key":"2024100317500718400_CIT0359","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.21037\/cco.2017.05.03","article-title":"Animal models of meningiomas","volume":"6","author":"Mawrin","year":"2017","journal-title":"Chin Clin Oncol"},{"issue":"3","key":"2024100317500718400_CIT0360","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.surneu.2007.06.031","article-title":"A comparison of the cell lines used in meningioma research","volume":"70","author":"Ragel","year":"2008","journal-title":"Surg Neurol."},{"issue":"2","key":"2024100317500718400_CIT0361","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1750-3639.2007.00109.x","article-title":"An orthotopic skull base model of malignant meningioma","volume":"18","author":"Baia","year":"2008","journal-title":"Brain Pathol (Zurich, Switzerland)"},{"issue":"4","key":"2024100317500718400_CIT0362","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/cancers11040545","article-title":"Identification of KIF11 as a novel target in meningioma","volume":"11","author":"Jungwirth","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024100317500718400_CIT0363","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1078-0432.CCR-22-2085","article-title":"Pharmacological landscape of FDA-approved anticancer drugs reveals sensitivities to ixabepilone, romidepsin, omacetaxine, and carfilzomib in aggressive meningiomas","volume":"29","author":"Jungwirth","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2024100317500718400_CIT0364","doi-asserted-by":"crossref","first-page":"102941","DOI":"10.1016\/j.ebiom.2020.102941","article-title":"GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma","volume":"59","author":"Negroni","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"2024100317500718400_CIT0365","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/neuonc\/not007","article-title":"Adoptive transfer of genetically modified Wilms\u2019 tumor 1\u2013specific T cells in a novel malignant skull base meningioma model","volume":"15","author":"Iwami","year":"2013","journal-title":"Neuro-Oncology."},{"issue":"9","key":"2024100317500718400_CIT0366","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/neuonc\/now031","article-title":"A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus","volume":"18","author":"Nigim","year":"2016","journal-title":"Neuro Oncol"},{"issue":"9","key":"2024100317500718400_CIT0367","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/labinvest.3700307","article-title":"Establishment of a benign meningioma cell line by hTERT-mediated immortalization","volume":"85","author":"P\u00fcttmann","year":"2005","journal-title":"Lab Invest."},{"issue":"2","key":"2024100317500718400_CIT0368","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11060-005-9076-y","article-title":"A genetic strategy to overcome the senescence of primary meningioma cell cultures","volume":"78","author":"Baia","year":"2006","journal-title":"J Neurooncol."},{"issue":"2","key":"2024100317500718400_CIT0369","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3171\/JNS\/2008\/108\/2\/0304","article-title":"A novel model of intracranial meningioma in mice using luciferase-expressing meningioma cells. Laboratory investigation","volume":"108","author":"Ragel","year":"2008","journal-title":"J Neurosurg."},{"issue":"36","key":"2024100317500718400_CIT0370","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1038\/onc.2012.436","article-title":"Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation","volume":"32","author":"Peyre","year":"2013","journal-title":"Oncogene."},{"key":"2024100317500718400_CIT0371","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-031-29750-2_15","article-title":"Preclinical models of meningioma","volume":"1416","author":"Jungwirth","year":"2023","journal-title":"Adv Exp Med Biol."},{"key":"2024100317500718400_CIT0372","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/B978-0-12-804280-9.00008-1","article-title":"Preclinical models of meningioma: Cell culture and animal systems","volume":"169","author":"Choudhury","year":"2020","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"2024100317500718400_CIT0373","doi-asserted-by":"crossref","first-page":"FSO190","DOI":"10.4155\/fsoa-2017-0003","article-title":"Ex vivo tumor culture systems for functional drug testing and therapy response prediction","volume":"3","author":"Meijer","year":"2017","journal-title":"Future Sci OA."},{"issue":"12","key":"2024100317500718400_CIT0374","doi-asserted-by":"crossref","first-page":"e1670019","DOI":"10.1080\/2162402X.2019.1670019","article-title":"Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery","volume":"8","author":"Sivakumar","year":"2019","journal-title":"Oncoimmunology"},{"key":"2024100317500718400_CIT0375","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jocn.2021.10.035","article-title":"Establishment and characterization of meningioma patient-derived organoid","volume":"94","author":"Chan","year":"2021","journal-title":"J Clin Neurosci."},{"issue":"15","key":"2024100317500718400_CIT0376","doi-asserted-by":"crossref","first-page":"e2205525","DOI":"10.1002\/advs.202205525","article-title":"Novel human meningioma organoids recapitulate the aggressiveness of the initiating cell subpopulations identified by ScRNA-Seq","volume":"10","author":"Huang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"2024100317500718400_CIT0377","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/neuonc\/noab155","article-title":"Newly established patient-derived organoid model of intracranial meningioma","volume":"23","author":"Yamazaki","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024100317500718400_CIT0378","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41467-020-18582-7","article-title":"Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma","volume":"11","author":"Magill","year":"2020","journal-title":"Nat Commun."},{"issue":"5","key":"2024100317500718400_CIT0379","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1097\/00006123-199711000-00027","article-title":"Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas","volume":"41","author":"Tonn","year":"1997","journal-title":"Neurosurgery."},{"issue":"1","key":"2024100317500718400_CIT0380","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s40478-023-01677-9","article-title":"A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas","volume":"11","author":"van de Weijer","year":"2023","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"2024100317500718400_CIT0381","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12935-024-03225-4","article-title":"Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma","volume":"24","author":"Kim","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"5","key":"2024100317500718400_CIT0382","doi-asserted-by":"crossref","first-page":"e057384","DOI":"10.1136\/bmjopen-2021-057384","article-title":"Development of \u2018Core Outcome Sets\u2019 for Meningioma in Clinical Studies (The COSMIC Project): Protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings","volume":"12","author":"Millward","year":"2022","journal-title":"BMJ Open"},{"issue":"5","key":"2024100317500718400_CIT0383","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro-Oncology."},{"issue":"42","key":"2024100317500718400_CIT0384","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/onc.2008.170","article-title":"AKT1 E17K in human solid tumours","volume":"27","author":"Bleeker","year":"2008","journal-title":"Oncogene."},{"issue":"7152","key":"2024100317500718400_CIT0385","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature."},{"issue":"5","key":"2024100317500718400_CIT0386","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-013-1187-5","article-title":"AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry","volume":"126","author":"Sahm","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2024100317500718400_CIT0387","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3171\/2016.8.JNS161076","article-title":"Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas","volume":"127","author":"Strickland","year":"2017","journal-title":"J Neurosurg."},{"issue":"3","key":"2024100317500718400_CIT0388","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2024100317500718400_CIT0389","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13000-016-0506-2","article-title":"Frequency of BRAF V600E mutations in 969 central nervous system neoplasms","volume":"11","author":"Behling","year":"2016","journal-title":"Diagn Pathol."},{"issue":"3","key":"2024100317500718400_CIT0390","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2024100317500718400_CIT0391","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/neuonc\/noab114","article-title":"MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma","volume":"23","author":"Bao","year":"2021","journal-title":"Neuro Oncol"},{"issue":"11","key":"2024100317500718400_CIT0392","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.prp.2007.07.009","article-title":"Genetic changes of CDH1, APC, and CTNNB1 found in human brain tumors","volume":"203","author":"Nikuseva-Marti\u0107","year":"2007","journal-title":"Pathol Res Pract."},{"issue":"1","key":"2024100317500718400_CIT0393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-31659-0","article-title":"An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures","volume":"8","author":"Collord","year":"2018","journal-title":"Sci Rep."},{"issue":"16","key":"2024100317500718400_CIT0394","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1158\/1078-0432.CCR-05-0411","article-title":"Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype","volume":"11","author":"Chapman","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"16","key":"2024100317500718400_CIT0395","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1158\/1078-0432.CCR-10-0891","article-title":"Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status","volume":"16","author":"Goutagny","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2024100317500718400_CIT0396","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11060-019-03333-6","article-title":"Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma","volume":"145","author":"Guyot","year":"2019","journal-title":"J Neurooncol."},{"issue":"3","key":"2024100317500718400_CIT0397","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11060-019-03333-6","article-title":"Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma","volume":"145","author":"Guyot","year":"2019","journal-title":"J Neurooncol."},{"issue":"2","key":"2024100317500718400_CIT0398","first-page":"F115","article-title":"The p16INK4a\/CDKN2A tumor suppressor and its relatives","volume":"1378","author":"Ruas","year":"1998","journal-title":"Biochim Biophys Acta."},{"issue":"1","key":"2024100317500718400_CIT0399","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1593\/neo.111574","article-title":"Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma","volume":"14","author":"Yang","year":"2012","journal-title":"Neoplasia"},{"issue":"10","key":"2024100317500718400_CIT0400","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/hmg\/9.10.1495","article-title":"Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas","volume":"9","author":"Gutmann","year":"2000","journal-title":"Hum Mol Genet."},{"issue":"4","key":"2024100317500718400_CIT0401","first-page":"771","article-title":"Mutational analysis of the DAL-1\/4.1B tumour-suppressor gene locus in meningiomas","volume":"16","author":"Martinez-Glez","year":"2005","journal-title":"Int J Mol Med."},{"issue":"10","key":"2024100317500718400_CIT0402","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jnen\/59.10.872","article-title":"Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases","volume":"59","author":"Perry","year":"2000","journal-title":"J Neuropathol Exp Neurol."},{"issue":"2","key":"2024100317500718400_CIT0403","doi-asserted-by":"crossref","first-page":"14433","DOI":"10.1038\/ncomms14433","article-title":"Integrated genomic analyses of de novo pathways underlying atypical meningiomas","volume":"8","author":"Harmanc\u0131","year":"2017","journal-title":"Nat Commun."},{"key":"2024100317500718400_CIT0404","doi-asserted-by":"crossref","first-page":"1076530","DOI":"10.3389\/fnins.2022.1076530","article-title":"Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma","volume":"16","author":"Zeng","year":"2022","journal-title":"Front Neurosci."},{"issue":"3","key":"2024100317500718400_CIT0405","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3171\/2022.7.JNS22953","article-title":"Impact of a cell cycle and an extracellular matrix remodeling transcriptional signature on tumor progression and correlation with EZH2 expression in meningioma","volume":"138","author":"Pereira","year":"2023","journal-title":"J Neurosurg."},{"issue":"4","key":"2024100317500718400_CIT0406","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1002\/cnr2.1369","article-title":"The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues","volume":"4","author":"Kar","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"4","key":"2024100317500718400_CIT0407","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/cancers13040903","article-title":"Molecular profiling of 22 primary atypical meningiomas shows the prognostic significance of 18q heterozygous loss and CDKN2A\/B homozygous deletion on recurrence-free survival","volume":"13","author":"Barresi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2024100317500718400_CIT0408","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3171\/2009.7.JNS09726","article-title":"Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway","volume":"112","author":"Johnson","year":"2010","journal-title":"J Neurosurg."},{"issue":"53","key":"2024100317500718400_CIT0409","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.18632\/oncotarget.27178","article-title":"New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses","volume":"10","author":"AlSahlawi","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"2024100317500718400_CIT0410","doi-asserted-by":"crossref","first-page":"CNS72","DOI":"10.2217\/cns-2021-0003","article-title":"Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas","volume":"10","author":"Maggio","year":"2021","journal-title":"CNS Oncol"},{"issue":"10","key":"2024100317500718400_CIT0411","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41556-019-0390-6","article-title":"KLF4 is involved in the organization and regulation of pluripotency-associated three-dimensional enhancer networks","volume":"21","author":"Di Giammartino","year":"2019","journal-title":"Nat Cell Biol."},{"issue":"1","key":"2024100317500718400_CIT0412","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1078-0432.CCR-18-0641","article-title":"Phosphoproteomic and kinomic signature of clinically aggressive grade I (1.5) meningiomas reveals RB1 signaling as a novel mediator and biomarker","volume":"26","author":"Parada","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2024100317500718400_CIT0413","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jmcb\/mjx023","article-title":"KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas","volume":"9","author":"Tang","year":"2017","journal-title":"J Mol Cell Biol."},{"issue":"1","key":"2024100317500718400_CIT0414","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-020-00912-x","article-title":"KLF4 K409Q\u2013mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment","volume":"8","author":"von Spreckelsen","year":"2020","journal-title":"Acta Neuropathologica Commun"},{"issue":"5","key":"2024100317500718400_CIT0415","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","article-title":"Associations of meningioma molecular subgroup and tumor recurrence","volume":"23","author":"Youngblood","year":"2021","journal-title":"Neuro Oncol"},{"issue":"237","key":"2024100317500718400_CIT0416","doi-asserted-by":"crossref","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: A synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med."},{"issue":"6","key":"2024100317500718400_CIT0417","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","article-title":"Merlin, a \u201cmagic\u201d linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival","volume":"11","author":"Stamenkovic","year":"2010","journal-title":"Curr Protein Pept Sci."},{"issue":"13","key":"2024100317500718400_CIT0418","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/sj.onc.1202531","article-title":"NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas","volume":"18","author":"Leone","year":"1999","journal-title":"Oncogene."},{"issue":"8","key":"2024100317500718400_CIT0419","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41417-023-00621-2","article-title":"Respective roles of Pik3ca mutations and cyproterone acetate impregnation in mouse meningioma tumorigenesis","volume":"30","author":"C\u00f4mes","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"2024100317500718400_CIT0420","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1056\/NEJMoa2100440","article-title":"Somatic PIK3CA mutations in sporadic cerebral cavernous malformations","volume":"385","author":"Peyre","year":"2021","journal-title":"N Engl J Med."},{"issue":"8","key":"2024100317500718400_CIT0421","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/jmg.2009.075721","article-title":"SMARCB1 mutations are not a common cause of multiple meningiomas","volume":"47","author":"Hadfield","year":"2010","journal-title":"J Med Genet."},{"key":"2024100317500718400_CIT0422","article-title":"LZTR1- and SMARCB1-Related Schwannomatosis","volume-title":"GeneReviews(\u00ae)","author":"Dhamija","year":"1993"},{"issue":"3","key":"2024100317500718400_CIT0423","first-page":"345","article-title":"SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas","volume":"19","author":"Boetto","year":"2017","journal-title":"Neuro-Oncology."},{"issue":"1","key":"2024100317500718400_CIT0424","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s40478-020-00994-7","article-title":"Meningioma cells express primary cilia but do not transduce ciliary Hedgehog signals","volume":"8","author":"Findakly","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"2024100317500718400_CIT0425","first-page":"9650184","article-title":"Novel SUFU frameshift variant leading to meningioma in three generations in a family with gorlin syndrome","volume":"2019","author":"Askaner","year":"2019","journal-title":"Case Rep Gen"},{"issue":"4","key":"2024100317500718400_CIT0426","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cancergen.2015.02.003","article-title":"Germline and somatic mutations in meningiomas","volume":"208","author":"Smith","year":"2015","journal-title":"Cancer Genet"},{"issue":"3","key":"2024100317500718400_CIT0427","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11060-018-2912-7","article-title":"TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas","volume":"139","author":"Biczok","year":"2018","journal-title":"J Neurooncol."},{"issue":"6122","key":"2024100317500718400_CIT0428","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science."},{"issue":"65","key":"2024100317500718400_CIT0429","doi-asserted-by":"crossref","first-page":"109228","DOI":"10.18632\/oncotarget.22650","article-title":"Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas","volume":"8","author":"Juratli","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"2024100317500718400_CIT0430","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jcp.25676","article-title":"The emerging role of TRAF7 in tumor development","volume":"232","author":"Zotti","year":"2017","journal-title":"J Cell Physiol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae082\/58576146\/noae082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/10\/1742\/59560208\/noae082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/10\/1742\/59560208\/noae082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T13:52:39Z","timestamp":1727963559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/10\/1742\/7663195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":430,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae082","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,2]]}}}